belumosudil mesylate · Kadmon Pharms Llc · NDA 214783
Rezurock
Earliest generic entry, as listed
14 Jul 2042
Blocked by patent: US 12097202. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 5 unexpired
7 Orange Book listing rows for 5 patents. FDA lists a patent once for each use code, and lists its pediatric extension as a separate row.
| Patent | Claims | Expires |
|---|---|---|
| US 12097202 | use U-4014 · sets the listed date | 14 Jul 2042 |
| US 11311541 | use U-3369 | 9 Apr 2035 |
| US 8357693 | drug substance, drug product, use U-4259 | 20 Jun 2034 |
| US 10183931 | use U-3246, U-4260 | 7 Oct 2033 |
| US 10183931 listing row | use U-3246 | 7 Oct 2033 |
| US 10183931 listing row | use U-4260 | 7 Oct 2033 |
| US 10696660 | use U-3246, U-4260 | 7 Oct 2033 |
| US 10696660 listing row | use U-3246 | 7 Oct 2033 |
| US 10696660 listing row | use U-4260 | 7 Oct 2033 |
Exclusivities · 1 unexpired
| ODE-362 | orphan drug (7 years) | 16 Jul 2028 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 214783 · 001 · RLD | tablet, oral | EQ 200MG BASE | 14 Jul 2042 |
Expired or delisted (1)
- NCE · 16 Jul 2026